Search Results

How can Health Technology Assessment reshape funding for social care?

Our latest analysis explores strategic approaches to HTA-informed funding and the vital role of support networks in building sustainable, equitable social care systems.

Read the full piece to see how these strategies are driving meaningful change.

#SyenzaNews #HealthEconomics #HealthcareInnovation #costeffectiveness #innovation

🚀 How is AI supercharging drug discovery timelines?

Bristol-Myers Squibb and NVIDIA are partnering to apply advanced AI models that can dramatically speed up the identification of promising new therapies. This collaboration aims to bring innovative treatments to patients faster while reducing development costs.

Read the full story to see what it means for pharma innovation.
#SyenzaNews #biotechnology #AIinHealthcare #ai #innovation

🚀 How are Gilead and GNese Portugal accelerating oncology evidence?

Through targeted grants, the partnership is strengthening real-world data generation and clinical insights to advance cancer care across Portugal.

Explore how this initiative is shaping the future of oncology research.
#SyenzaNews #oncology #pharmaceuticals #innovation

Exciting FDA approval! Gedatolisib plus fulvestrant delivers strong PFS benefits (HRs 0.24 & 0.33) for HR+/HER2- breast cancer patients, offering meaningful new hope. Read the full Syenza News article to explore the data. #FDAapproval #BreastCancer #Oncology #ClinicalTrials #Healthcare

What opportunities do EIT Health’s 2027 grants unlock for Europe’s health innovators?

New provisions prioritize cross-border collaboration, sustainability, and digital solutions, with major implications for startups, researchers, and health systems seeking funding.

Explore how these changes could shape your next project.
#SyenzaNews #HealthcareInnovation #HealthTech #innovation

📊 How is Portugal turning hospital data into powerful population health insights?

A new data platform is enabling deeper analysis of health trends, outcomes, and resource use across patient populations.

Explore how this approach is advancing data-driven decision-making in healthcare.
#SyenzaNews #digitalhealth #HealthTech #DigitalTransformation #datascience

Could a Phase III win make botulinum toxin a dual‑indication migraine therapy? 🔬📈

A recent Phase III program showed positive efficacy and safety for botulinum toxin in episodic migraine, supporting regulatory filings that could expand its label beyond chronic migraine—opening new treatment options for patients and commercial opportunities for sponsors.

Read the full article to learn trial highlights, regulatory implications, and what this means for clinicians and market access teams.

#SyenzaNews #clinicaltrials #drugdevelopment #MarketAccess #innovation

Could earlier surveillance after TAVR unlock better outcomes at lower cost? 💡📈

A new analysis finds that proactive early‑post‑TAVR surveillance has the potential to be cost‑effective — and in many modeled scenarios, economically dominant — by improving patient outcomes while reducing downstream costs. The piece highlights key assumptions, sensitivity analyses, and implications for clinicians, payers, and policymakers.

Read the full article to understand the evidence and what it means for adopting early surveillance strategies.

#SyenzaNews #HealthEconomics #HealthTechnology #costeffectiveness #MarketAccess

Can practice-level telehealth really improve quality and outcomes for people with chronic conditions? 📲

This article distills evidence and practice examples showing how well-integrated telehealth—backed by workflow redesign, staff training, and equity-focused access—can boost continuity of care, adherence, and patient engagement while revealing common implementation pitfalls.

Read the full article for practical steps, metrics to track, and policy considerations to make telehealth work for chronic care. ✅

#SyenzaNews #digitalhealth #HealthTech #DigitalTransformation #healthcarepolicy

Are large language models ready to reshape evidence-based medicine? 🤖🔬

This article examines how LLMs can accelerate literature synthesis, support clinical decision-making, and streamline guideline development — while also outlining the key risks (hallucinations, bias, validation gaps) and practical safeguards for safe, regulated deployment.

Read the full piece to get evidence-based recommendations, evaluation frameworks, and actionable steps for integrating LLMs into clinical workflows.

#SyenzaNews #AIinHealthcare #HealthTech #ai #innovation

Could integrating pharmacogenomics into Africa’s essential medicines lists transform patient outcomes? 🧬🌍

This article outlines how using population-specific genetic data can reduce adverse drug reactions, optimize dosing, and improve therapeutic effectiveness—while highlighting the policy, capacity-building, and equity measures required for implementation.

Read the full piece for practical recommendations and policy pathways to bring precision medicine into routine care across African health systems.

#SyenzaNews #pharmaceuticals #precisionmedicine #healthcarepolicy #innovation

Could Portugal become Europe’s next biotech powerhouse? 🧬

Portugal is leveraging policy support, growing VC, and strong research–industry links to build the talent, infrastructure and clusters that help biotech startups scale and attract international partners. This article breaks down the key catalysts — funding, regulation, talent and ecosystems — shaping Portugal’s role in Europe’s life sciences landscape.

Read the full analysis to see where the opportunities are for founders, investors and policymakers.

#SyenzaNews #biotechnology #HealthTech #innovation #MarketAccess